https://vasomune.com/a-new-flu-drug-works-astoundingly-well-by-not-targeting-the-flu-at-all/2019-07-19T10:49:37-04:00https://vasomune.com/preventing-the-flu-researchers-looking-for-a-new-approach/2019-07-19T10:49:37-04:00https://vasomune.com/36th-annual-jpm-healthcare-conference/2020-01-15T17:00:39-05:00https://vasomune.com/vasomune-therapeutics-and-anges-inc-enter-into-a-multi-million-dollar-global-co-development-agreement-to-advance-an-innovative-platform-targeting-vascular-leakage/2019-07-19T10:49:37-04:00https://vasomune.com/vasomune-therapeutics-is-at-the-38th-j-p-morgan-healthcare-conference/2020-01-16T18:37:09-05:00https://vasomune.com/vasomune-lead-investigational-medication-is-connected-to-fight-against-coronavirus/2020-02-28T11:37:56-05:00https://vasomune.com/the-covid-19-coronavirus-leads-to-acute-respiratory-distress-syndrome/2023-02-09T18:47:46-05:00https://vasomune.com/vasomune-appoints-meenu-chhabra-to-its-board-of-directors/2020-05-12T11:43:51-04:00https://vasomune.com/vasomune-announces-clinical-and-scientific-advisory-board/2020-05-15T15:49:19-04:00https://vasomune.com/vasomune-receives-a-us-2-8-million-prmrp-grant-from-the-us-department-of-defense-to-develop-av-001-for-the-treatment-of-ali-ards-of-any-cause-including-covid-19/2020-08-18T12:43:37-04:00https://vasomune.com/learn-more-about-vasomunes-partnership-with-the-university-of-iowas-covid-19-drug-manufacturing/2020-08-18T13:02:19-04:00https://vasomune.com/vasomune-announces-fda-allowance-of-ind-application-for-av-001-for-the-treatment-of-hospitalized-patients-with-covid-19/2020-12-17T11:34:02-05:00https://vasomune.com/vasomune-announces-initiation-of-the-first-in-human-clinical-trial-of-a-potential-vascular-normalization-covid-19-treatment/2020-12-17T11:49:09-05:00https://vasomune.com/vasomune-is-pleased-to-announce-the-government-of-canadas-investment-in-av-001-targeting-covid-19/2021-03-17T13:17:34-04:00https://vasomune.com/vasomune-announces-preliminary-positive-phase-1-clinical-trial-results-for-vascular-normalization-therapy/2021-03-25T09:37:54-04:00https://vasomune.com/vasomune-announces-government-financial-support-for-the-development-of-covid-19-therapeutic/2022-01-18T09:50:43-05:00https://vasomune.com/vasomune-and-anges-announce-first-patient-enrolled-in-phase-2a-clinical-study-evaluating-av-001-for-the-treatment-of-severe-covid-19-disease/2022-01-18T09:41:23-05:00https://vasomune.com/607-2/2023-11-14T10:45:08-05:00https://vasomune.com/american-thoracic-society-selects-vasomune-therapeutics-inc-to-present-the-av-001-development-update-at-the-2024-respiratory-innovation-summit/2024-04-24T15:08:46-04:00https://vasomune.com/vasomune-therapeutics-receives-us-fda-fast-track-designation-for-novel-investigational-medicine-av-001/2024-05-30T15:01:04-04:00